0001104659-23-080686.txt : 20230713 0001104659-23-080686.hdr.sgml : 20230713 20230713135906 ACCESSION NUMBER: 0001104659-23-080686 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230711 FILED AS OF DATE: 20230713 DATE AS OF CHANGE: 20230713 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SBLENDORIO GLENN CENTRAL INDEX KEY: 0001277478 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36080 FILM NUMBER: 231086434 MAIL ADDRESS: STREET 1: 3 TIMES SQAURE, 12TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IVERIC bio, Inc. CENTRAL INDEX KEY: 0001410939 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208185347 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: (609) 474-6755 MAIL ADDRESS: STREET 1: 8 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Ophthotech Corp. DATE OF NAME CHANGE: 20070828 4 1 tm2321002-7_4seq1.xml OWNERSHIP DOCUMENT X0407 4 2023-07-11 1 0001410939 IVERIC bio, Inc. ISEE 0001277478 SBLENDORIO GLENN C/O IVERIC BIO, INC. 8 SYLVAN WAY PARSIPPANY NJ 07054 1 1 0 0 Chief Executive Officer 0 Common Stock 2023-07-11 4 D 0 239275 D 0 D Restricted Stock Units 2023-07-11 4 D 0 23750 D Common Stock 23750 0 D Restricted Stock Units 2023-07-11 4 D 0 73315 D Common Stock 73315 0 D Restricted Stock Units 2023-07-11 4 D 0 94500 D Common Stock 94500 0 D Restricted Stock Units 2023-07-11 4 D 0 150000 D Common Stock 150000 0 D Stock Option (Right to Buy) 33.27 2023-07-11 4 D 0 6949 D 2023-10-23 Common Stock 6949 0 D Stock Option (Right to Buy) 37.00 2023-07-11 4 D 0 15000 D 2024-05-20 Common Stock 15000 0 D Stock Option (Right to Buy) 48.30 2023-07-11 4 D 0 7000 D 2025-06-01 Common Stock 7000 0 D Stock Option (Right to Buy) 44.90 2023-07-11 4 D 0 150000 D 2026-03-31 Common Stock 150000 0 D Stock Option (Right to Buy) 4.52 2023-07-11 4 D 0 260000 D 2027-01-29 Common Stock 260000 0 D Stock Option (Right to Buy) 2.94 2023-07-11 4 D 0 325000 D 2027-12-18 Common Stock 325000 0 D Stock Option (Right to Buy) 1.45 2023-07-11 4 D 0 133500 D 2028-12-11 Common Stock 133500 0 D Stock Option (Right to Buy) 5.22 2023-07-11 4 D 0 190000 D 2029-12-08 Common Stock 190000 0 D Stock Option (Right to Buy) 7.50 2023-07-11 4 D 0 293150 D 2030-12-17 Common Stock 293150 0 D Stock Option (Right to Buy) 14.83 2023-07-11 4 D 0 252000 D 2031-12-16 Common Stock 252000 0 D Stock Option (Right to Buy) 22.57 2023-07-11 4 D 0 300000 D 2032-12-19 Common Stock 300000 0 D On July 11, 2023, pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated April 28, 2023, by and among IVERIC bio, Inc. ("IVERIC"), Astellas US Holding, Inc., Berry Merger Sub, Inc. ("Merger Sub") and, solely as provided by Section 8.10(b) of the Merger Agreement, Astellas Pharma Inc. ("Astellas"), Merger Sub merged with and into IVERIC, with IVERIC surviving the merger and becoming an indirect wholly owned subsidiary of Astellas (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of IVERIC common stock ("Common Stock") reported in this Form 4 was automatically cancelled and was converted into the right to receive $40.00 in cash, without interest and less any applicable withholding taxes. Each IVERIC restricted stock unit ("RSU") represented the contingent right to receive one share of Common Stock upon vesting of the RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU reported in this Form 4 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) $40.00, multiplied by (2) the number of shares of Common Stock subject to such RSU. Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Common Stock ("IVERIC Option") reported in this Form 4 which had a per share exercise price less than $40.00 was cancelled and converted into the right to receive a cash payment (subject to any applicable tax withholding) equal to (1) the excess of $40.00 over the exercise price per share of Common Stock underlying such IVERIC Option, multiplied by (2) the total number of shares of Common Stock subject to such IVERIC Option immediately prior to the Effective Time (without regard to vesting). Each IVERIC Option reported in this Form 4 which had a per share exercise price $40.00 or greater was cancelled with no consideration payable in respect thereof. /s/ Todd D.C. Anderman, as Attorney-in-Fact for Glenn P. Sblendorio 2023-07-13